Product Datasheet  
NF- kappaB p65 (Phospho-Ser281) Antibody  
Catalog Number: 12000  
Technical:tech@swbio.com  
Information:info@swbio.com  
Description  
  • host_species:  
  • Rabbit
  • Amount:  
  • 100μgμg
  • Swiss-Prot No.:  
  • Swiss-Prot#: Q04206;
    NCBI Gene#: 5970;
    NCBI Protein#: NP_001138610.1
  • Form of Antibody:  
  • Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
  • Storage:  
  • Store at -20˚C/1 year
  • Immunogen:  
  • Peptide sequence around phosphorylation site of serine281(E-L-S(p)-E-P) derived from Human NF- kappaB .
  • reactivity:  
  • Hu Ms Rt
  • appl_detail:  
  • Western blotting: 1:500~1:1000
  • other_names:  
  • NFKB3; Nuclear factor NF-kappa-B p65 subunit; RELA; TF65; p65
  • Purification:  
  • Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
  • Specificity:  
  • The antibody detects endogenous level of NF- kappaB p65 only when phosphorylated at serine 281.
  • Applications:  
  • WB
  • Background:  
  • NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex.

    Hochrainer K, Racchumi G, Anrather J (2013)J Biol Chem 288, 285-93. Dai Y, et al. (2008) Clin Cancer Res 14, 549-58. Seldon MP, et al. (2007)J Immunol 179, 7840-51.




 
© Signalway Biotechnology All Rights Reserved.